SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Calamity Jane — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMartha Canary
Date of birth1856-05-01
IdentifiersMRN HR-NI008-SYN-TD; SSN (made up) 000-08-9532
Document date1901-03-09
AuthorRuth Ann Kessler, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

One-week review after outpatient withdrawal, seen the same day by addiction medicine. [S]

History of Present Illness

Ms. Canary returns one week after intake and is seen by Dr. Two Bulls-Harmon of addiction medicine on the same day. Her last drink was on the morning of her intake visit. The clinic nurse saw or called her every day: her CIWA-Ar was 10 on the second day with tremor, sweats and poor sleep, then fell each day to 2 today. She took the five-day gabapentin schedule as written and finished it three days ago, had the three thiamine injections, and took the potassium for five days and the magnesium as prescribed. She has had no seizures, hallucinations or confusion. Her friend stayed close during the worst days. She is eating more. The intake tests showed no HIV or hepatitis C, no hepatitis B infection or immunity, a urine test with no opioids, fentanyl or other drugs, and a negative pregnancy test. The community health worker helped her apply for Medicaid and SNAP, and she has met the peer recovery specialist once. She would like to stay off alcohol completely and wants to know about medicines that help. [S]

ElementDetail
Last drinkMorning of the intake visit, seven days ago
WithdrawalCIWA-Ar highest 10 on day two; 2 today; no seizure, hallucinations or confusion
GabapentinFive-day schedule finished three days ago
Intake resultsHIV and hepatitis C negative; hepatitis B not infected and not immune; urine test negative for opioids and fentanyl; pregnancy test negative
BenefitsMedicaid and SNAP applications submitted

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; appetite returning
GastrointestinalNegativeNo vomiting, abdominal pain or black stools
NeurologicalNegativeTremor gone; no seizures, confusion or unsteadiness
PsychiatricPositiveLow and restless in the evenings; cravings; no hallucinations; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Gabapentin 300 mg oral capsule on a written five-day schedule for alcohol withdrawal: 300 mg in the morning, 300 mg in the afternoon and 600 mg at bedtime for three days, then 300 mg twice daily on day four, 300 mg at bedtime on day five, then stop; dispensed for the five days onlyPer the written five-day scheduleOral route1901-03-02 to 1901-03-06completedS
Thiamine 100 mg by intramuscular injection once daily for three days, given in the clinic100 mg intramuscularly once daily for three daysIntramuscular route1901-03-02 to 1901-03-04completedS
Thiamine 100 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-05activeS
Folic acid 1 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-02activeS
Potassium chloride extended-release 20 mEq oral tablet, one tablet daily with food for five daysOne tablet daily with food for five daysOral route1901-03-02 to 1901-03-06completedS
Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeksOne tablet twice daily for two weeksOral route1901-03-02 to 1901-03-16completedS
Naltrexone 50 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-09 to 1901-03-30completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1901-03-09Body height165cmS
1901-03-09Body weight50.4kgS
1901-03-09Body mass index (BMI) [Ratio]18.5kg/m2S
1901-03-09Systolic blood pressure128mm[Hg]S
1901-03-09Diastolic blood pressure82mm[Hg]S
1901-03-09Heart rate84/minS
1901-03-09Respiratory rate16/minS
1901-03-09Body temperature36.8CelS
1901-03-09Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1901-03-09Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
1901-03-09Magnesium [Mass/volume] in Serum or Plasma1.8mg/dL1.7-2.3 mg/dLNormalS

Physical Exam

Vital signs recorded on 1901-03-09; see the Vital Signs section. [S]

SystemFinding
GeneralAlert; blood pressure 128/82, pulse 84, temperature 36.8 °C
EyesNo nystagmus; no scleral icterus
NeurologicalNo tremor with arms outstretched; gait steady; oriented
AbdomenSoft and non-tender; liver edge not palpable

Problems

ProblemClinical statusVerificationCodeProvenance
Alcohol use disorder, severe (nine of eleven DSM-5-TR criteria), daily drinking of about a pint of whiskey with heavier binges for many years; synthetic modern episode linked to her documented lifelong heavy drinkingactiveconfirmed F10.20S — Synthetic modern coding; DSM-5-TR severe alcohol use disorder maps to F10.20 when withdrawal is coded separately. Person-first language; not a claim about her real diagnosis.
Alcohol withdrawal, mild, at low risk of complications (PAWSS 3, CIWA-Ar 9 at intake; no past seizures or delirium tremens), managed as an outpatient with daily nurse checksresolvedconfirmed F10.230S — Synthetic withdrawal episode; resolved by the one-week visit.
Raised liver enzymes (AST 96, ALT 44, GGT 240 U/L) with a FIB-4 index of 3.93, above the cut point for possible advanced fibrosis; liver stiffness measurement plannedactiveconfirmed R74.01S — Synthetic presenting finding; superseded when elastography and the clinical picture supported alcohol-associated steatotic liver disease.
Depressive symptoms during heavy drinking (PHQ-9 14, item 9 scored 0); whether they are alcohol-induced or an independent depression to be judged after two to four weeks without alcoholactiveprovisional F32.AS — Synthetic provisional finding; resolved as the PHQ-9 fell to 5 after ten weeks without alcohol, consistent with alcohol-induced depressive symptoms. Not a claim about her real mood.
Daily chewing tobacco for many years; not ready to stop at intakeactiveconfirmed F17.220S — Synthetic modern coding anchored to the documented chewing tobacco.
Underweight (BMI 18.4) with poor food intake, low folate, magnesium and phosphate, and slightly low albuminactiveconfirmed R63.6S — Synthetic finding anchored to a contemporary impression of poor nutrition (R).
Housing instability: staying in a spare room at a friend's house, with nowhere to go if that ends; has stayed in shelters in past wintersactiveconfirmed Z59.811S — Synthetic social need anchored to her documented poverty and moves from town to town.
Food insecurity: often goes without meals at the end of the monthactiveconfirmed Z59.41S — Synthetic social need anchored to her documented poverty.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Self-managementDrinking since the last visit (her own account, day by day), cravings and triggersEvery visitCompleted todayNo alcohol since the morning of intake; cravings in the evenings
LaboratoryPEth, explained as part of care and not as a test of honestyAt baseline and about every one to two monthsUp to date820 ng/mL at intake; next at four weeks
ExaminationWithdrawal (CIWA-Ar) and transfer criteriaDaily during withdrawal managementCompleted todayDaily nurse checks for six days: highest 10 on day two, 2 today; no transfer needed
LaboratoryThiamine, folate and electrolytesThiamine before glucose and through recovery; electrolytes rechecked within a week if lowCompleted todayThree thiamine injections, then tablets; potassium 3.9 mmol/L and magnesium 1.8 mg/dL after replacement
Medication safetyMedicine for alcohol use disorder: adherence, side effects, opioid exposureEvery visitCompleted todayNaltrexone 50 mg started today; urine test negative for opioids and fentanyl; wallet card given
LaboratoryLiver enzymes on naltrexoneBaseline, within the first months of treatment, then periodicallyUp to dateBaseline at intake: AST 96, ALT 44 U/L; recheck at four weeks
ImagingLiver fibrosis: FIB-4, transient elastography, albumin, INR, plateletsElastography when FIB-4 is above 2.67, repeated after months without alcoholOrderedFIB-4 3.93 at intake; transient elastography booked for the four-week visit
ExaminationWeight, meals and food accessEvery visitCompleted todayWeight 50.4 kg, up 0.4 kg; eating more; SNAP application submitted
SurveyDepression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcoholAt baseline, after two to four weeks without alcohol, then at least monthly while symptoms persistDuePHQ-9 14 at intake during heavy drinking; repeat at four weeks
SurveySuicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; the rifle stored with her friend; 988 card carried
Self-managementPeer recovery support and mutual-help meetingsWeekly peer contact; meetings of her choiceCompleted todayMet the peer recovery specialist once; considering a women's meeting
Self-managementHousing, food, income and health coverageEvery visitCompleted todayMedicaid and SNAP applications submitted with the community health worker
Self-managementChewing tobaccoEvery visitCompleted todayChewing tobacco daily; not ready to stop
Medication safetyNaloxoneReassess at every visitNot indicatedNo opioid use, and the urine test showed no opioids or fentanyl
ReferralAddiction medicine consultationAt the start of treatmentCompleted todaySeen by Dr. Two Bulls-Harmon today

Goal progress:

Guideline basis: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The Healthcare Professional's Core Resource on Alcohol (2026); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Four-week review in three weeks with blood tests, PEth, elastography and the PHQ-9. Weekly peer contact. Call the clinic, the peer specialist or 988 if needed. Next scheduled visit 1901-03-30: four-week review: naltrexone and the change to a monthly injection, liver stiffness, mood after four weeks without alcohol, and benefits. [S]